|
DAY 1 | Wednesday 14th May 2008
|
Morning plenary session
Meeting the vaccine innovation challenge: How will industry, NGOs and the public sector overcome existing scientific and economic barriers to deliver vaccines for the world?
|
| Followed by your choice of 3 highly interactive parallel sessions: |
|
Focus session 1
|
Or | Focus session 2
|
Or | Workshop
|
| Adjuvant R&D and regulatory update: What progress is being made in terms of improving both safety and immunogenicity? |
DNA vaccines and viral vectors: After the hype, are they about to deliver?
|
Removing the cold chain - how are novel delivery and stabilisation technologies enabling the efficient and effective delivery of vaccines to the developing world?
|
THEN | Afternoon plenary session
|
| Where next for AIDS vaccines? |
|
|
DAY 2 | Thursday 15th May 2008
|
|
Morning plenary session
Anticipating and accessing emerging vaccine markets to secure long-term competitive advantage
|
| Followed by your choice of 3 highly interactive parallel sessions: |
|
Focus session 1
|
OR | Focus session 2 |
OR | Workshop |
|
Delivering the latest market expectations and clinical data for vaccines against nosocomial infections
|
Therapeutic vaccines update: What is the latest progress with leading candidates in clinical development?
• How and when will they reach the market?
|
How can we improve immune response in elderly and immunosuppressed populations?
|
|
THEN | Afternoon plenary session
Honing your corporate development model in light of ongoing partnering trends in the vaccine sector
|
|
|
DAY 3 | Friday 16th May 2008
|
Morning plenary session
Moving forwards, how can the industry best demonstrate the value of novel vaccines...
|
| Followed by your choice of 3 highly interactive parallel sessions: |
| Focus session 1 |
OR | Focus session 2 |
OR | Breakout session |
|
What progress is being made in developing and harmonising regulations in key areas of concern for the vaccine industry?
|
Which vaccine manufacturing technologies hold the key to delivering reductions in cost and time-to-market?
|
What is the business/value proposition for your organisation in utilising a novel adjuvant?
|
|
